MI:RNA has closed an oversubscribed $3.6M funding round, accelerating our mission to deliver faster, more precise, and more accessible diagnostic solutions for veterinarians and producers worldwide.
As CEO and founder Dr. Eve Hanks shared: “The opportunity to deploy our diagnostic platform globally through our partner laboratories is taking shape, and this positive support from our investors not only validates the strength of our technology and market approach, it also accelerates our continued development and technological advancement as we work to bring critical diagnostic solutions into the hands of those who need them most.”